The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: Comparison with ultrasonography and magnetic resonance imaging
Authors:
- 29 October 2009
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 102 (5) , 392-397
Abstract
Background Recently PET is emerged as a method to estimate the response of neoadjuvant chemotherapy (NAC) in advanced breast cancer. This study is aimed to estimate the predictive role of PET CT and other imaging modalities (ultrasound, MRI) through NAC. Methods PET CT was acquired before and after NAC from 41 patients. Pathologic results were classified as pathological complete response (pCR) and non‐pCR. The results of clinical responses were assessed with imaging indexes (postTx, postchemotherapy size or peak standardized uptake values (pSUV); delta, the size difference between treatment; RR, reduction rate of tumor size or pSUV), and they were compared with pathologic results. Results Seven patients (17.1%) showed pCR. As a result of comparison of the image index, all image indexes of MRI were predictive for pCR (P < 0.05). In contrast, only delta and RR of US, RR of PET CT were significant. The area under curve of delta and RR in MRI were higher (0.91, 0.90) than US (0.83, 0.80) and PET CT (0.62, 0.72). The MRI is superior to the US or PET CT. Conclusions We have concluded that the MRI is better than PET CT for monitoring the effect of NAC in advanced breast cancer. J. Surg. Oncol. 2010;102:392–397.Keywords
This publication has 19 references indexed in Scilit:
- MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapyCancer, 2007
- Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?Journal of Surgical Oncology, 2007
- [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Primary Systemic Therapy of Breast CancerThe Oncologist, 2006
- Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant ChemotherapyBreast Cancer Research and Treatment, 2005
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast CancerJournal of Clinical Oncology, 2005
- The Use of Alternate, Non–Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized TrialJournal of Clinical Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal of Cancer, 1999
- Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapyThe American Journal of Surgery, 1998